Breyanzi (lisocabtagene maraleucel) / BMS 
Welcome,         Profile    Billing    Logout  
 5 Diseases   11 Trials   11 Trials   982 News 


12345678910111213...2021»
  • ||||||||||  Journal:  T cell malignancies after CAR T?cell therapy in the DESCAR-T registry. (Pubmed Central) -  Apr 16, 2025   
    All multiple myeloma patients received idecabtagene vicleucel, with none receiving ciltacabtagene autoleucel...Thus, the development of this secondary T?cell malignancy might be linked to the use of CAR?T?cell therapy. In conclusion, our findings indicate a very low risk of T?cell malignancy after CAR?T?cell therapy.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Jaypirca (pirtobrutinib) / Eli Lilly, Breyanzi (lisocabtagene maraleucel) / BMS
    Journal:  Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia. (Pubmed Central) -  Apr 10, 2025   
    Additionally, novel BTK-directed therapies and T-cell engaging bispecific antibodies have achieved promising responses in pre-treated CLL in early phase clinical trials. Here, we review the mechanisms responsible for resistance to cBTKi and venetoclax in CLL, appraise recent evidence supporting the use of each of the novel and emerging agent classes and then suggest innovative treatment strategies incorporating these in patients with double-refractory disease, remaining cognizant of the variability of access to novel therapies and clinical trials.
  • ||||||||||  Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
    Journal:  Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome. (Pubmed Central) -  Mar 24, 2025   
    This data suggests that ALCmax is a good marker for response to CAR-T therapy and encourages better understanding of the factors influencing ALC levels between the CAR-T products and disease subtypes. Our results suggest that and that it is important to monitor iP kinetics more carefully because patients treated with ide-cel complicate severe hypophosphatemia, regardless of CRS severity.
  • ||||||||||  Jaypirca (pirtobrutinib) / Eli Lilly, Breyanzi (lisocabtagene maraleucel) / BMS
    BC3: Captivating Updates in Chronic Lymphocytic Leukemia: A Shifting Paradigm (Oregon Ballroom 202-203) -  Feb 17, 2025 - Abstract #HOPA2025HOPA_63;    
    Examine the use of the non-covalent BTK inhibitor, pirtobrutinib, and CAR T-cell therapy in relapsed/refractory CLL4. Design a treatment algorithm for relapsed/refractory CLL
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
    Journal:  Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. (Pubmed Central) -  Feb 12, 2025   
    In conclusion, CD19 CAR T-cell therapy infrequently delivers long term disease control in BL. Further investigation is needed to determine the most effective alternative management of these patients.
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
    T-ICAHT: A NOVEL GRADING SYSTEM TO CHARACTERIZE THROMBOCYTOPENIA AND ITS PROGNOSTIC RELEVANCE IN CAR-T THERAPY (Raffaello (Spadolini -1)) -  Feb 5, 2025 - Abstract #EBMT2025EBMT_3181;    
    Using this system, we identified high-grade thrombocytopenia (G?3) in over 20% of patients. Importantly, T-ICAHT grades were prognostically significant, stratifying survival risk independently of established risk factors.
  • ||||||||||  ANALYSIS OF MAJOR ADVERSE CARDIAC EVENTS (MACE) AND SURVIVAL OUTCOMES BY CAR-T SUBTYPE: CD-19 VERSUS BCMA DIRECTED THERAPY IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS (Firenze (Spadolini 1)) -  Feb 5, 2025 - Abstract #EBMT2025EBMT_1903;    
    Though numerically higher for CD19 CAR-T there was no significant difference between CAR-T cohorts per targeted antigens. Additionally, no difference was found in cardiovascular or all-cause readmissions, CRS incidence, or Tocilizumab utilization.Conversely, BCMA CAR-T therapy demonstrated a higher risk of earlier mortality in comparison to CD19 CAR-T therapy and a more profound decrease of fibrinogen levels during treatment.Further research is warranted to explore the relationship between CAR-T therapy and cardiovascular toxicities including the underlying effect of the activation of the inflammatory pathway on outcomes develop effective preventative strategies.
  • ||||||||||  ANALYSIS OF MAJOR ADVERSE CARDIAC EVENTS (MACE) AND SURVIVAL OUTCOMES BY CAR-T SUBTYPE: CD-19 VERSUS BCMA DIRECTED THERAPY IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS (ePoster Area) -  Feb 5, 2025 - Abstract #EBMT2025EBMT_1902;    
    Though numerically higher for CD19 CAR-T there was no significant difference between CAR-T cohorts per targeted antigens. Additionally, no difference was found in cardiovascular or all-cause readmissions, CRS incidence, or Tocilizumab utilization.Conversely, BCMA CAR-T therapy demonstrated a higher risk of earlier mortality in comparison to CD19 CAR-T therapy and a more profound decrease of fibrinogen levels during treatment.Further research is warranted to explore the relationship between CAR-T therapy and cardiovascular toxicities including the underlying effect of the activation of the inflammatory pathway on outcomes develop effective preventative strategies.
  • ||||||||||  Yescarta (axicabtagene ciloleucel) / Gilead
    Journal:  Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel. (Pubmed Central) -  Jan 30, 2025   
    Higher prolonged thrombocytopenia rates were observed in patients with axi-cel V2Vt 28 to <40 days or 40+ days compared with <28 days (OR 1.44 or 1.95, respectively). Together, these results show the impact of V2Vt on patient outcomes with axi-cel therapy and that earlier infusion with CD19-CAR therapies may be beneficial.
  • ||||||||||  Bispecific Antibody Treatment for Diffuse Large B Cell Lymphoma, a Real-World Evidence (RWE) Study (HCC Exhibit Hall 3; In-Person) -  Jan 15, 2025 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1609;    
    Evidence from landmark trials for the FDA-approved products epcoritamab and glofitamab suggests that BsAb therapy is effective in relapsed/refractory disease...Median prior lines of therapy was 2.5 (range 0-10), with 60% having prior CAR T including axi-cel (62%) and liso-cel (14%)...Importantly, almost half of pts treated would likely not have qualified for BsAb therapy on trial, however, efficacy appeared to be preserved. Thus, our findings support the use of BsAbs including in pts with compromised functional status and comorbidities.
  • ||||||||||  A Comparison of Survival in Younger Vs Older Patients Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) for Aggressive B-Cell Lymphoma (HCC Ballroom A; In-Person) -  Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1355;    
    Methods We performed a multicenter, retrospective study of pts with R/R LBCL treated with anti-CD19 CART therapy across 14 US institutions from 2018-2024...Older pts were more likely to be treated with 4-1BB constructs (tisa-cel or liso-cel) rather than CD28 construct axi-cel (p< 0.01) and more likely to have an IPI of 3-5 at time of CART infusion (p=0.01)...For our oldest pts age ?80, CART provides similar safety and therapeutic benefits comparable to younger pts and pivotal trials. CART should be prioritized as a curative option in these pts with consideration for functional status and toxicities.
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
    CAR T Outcomes in Patients with High-Grade B-Cell Lymphoma Not Otherwise Specified (HGBL-NOS): A CIBMTR Analysis (HCC Exhibit Hall 3; In-Person) -  Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1211;    
    We observed a small subset of patients achieving a durable response; however the overall results were disappointing with lower ORR, OS and PFS compared to published reports. Our analysis highlights that improving clinical outcomes for HGBL-NOS patients remains an unmet need even in the current era of lymphoma immunotherapies.
  • ||||||||||  Gamifant (emapalumab-lzsg) / SOBI
    Emapalumab for the Treatment of Toxicities Associated with CD19 CAR-T Cells in Adult Patients (HCC Exhibit Hall 3; In-Person) -  Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1061;    
    The majority of patients clinically and biochemically improved within 48-hours and 75% remain in remission to date. All patients were documented as having high-grade CRS at the time of first ema dose but could be classified as IEC-HS.
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Yescarta (axicabtagene ciloleucel) / Gilead
    Assessment of Lymphodepletion Strategies in CAR-T Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (HCC Exhibit Hall 3; In-Person) -  Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1035;    
    This retrospective study included 90 r/r DLBCL patients treated with axi-cel (74.4%) or liso-cel (25.6%) at UPMC from 06/2018-10/2023...These data suggest that Benda LD could benefit patients with cytopenias or poor performance status. Larger, prospective studies are needed.
  • ||||||||||  CAR-Tography: A Comprehensive Atlas of Early CAR-T Toxicity at Single-Day Resolution (HCC Exhibit Hall 3; In-Person) -  Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1026;    
    Leveraging >100,000 serial data points from a large, deeply annotated international cohort, we developed a new metric, the CTI, to quantify the main toxicity burden in CAR-T patients. Employing an unsupervised approach, we defined biologically distinct and prognostically relevant toxicity phenotypes, underlining that CAR-T toxicities should be understood as more than the sum of their parts.
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
    When Can We Define Disease-Free Status Post-CAR-T Therapy in LBCL? Findings from Dynamic Landmark Analyses (HCC Exhibit Hall 3; In-Person) -  Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1024;    
    Our findings indicate that with Tisa-cel, progression can be observed up to 2 years. whereas patients maintaining remission at one year following Axi-cel and Liso-cel have a very low probability of relapse, underscoring their potential for achieving sustained disease-free survival.